PCM
ZVRA icon

Prelude Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Prelude Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Buy
25,941
+14,441
+126% +$130K 0.02% 814
2025
Q4 		$103K Sell
11,500
-4,100
-26% -$38.8K 0.01% 1179
2025
Q3 		$148K Buy
+15,600
New +$156K 0.01% 1001

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Prelude Capital Management's ZVRA Position: Q1 2026 in Review

Prelude Capital Management increased its Zevra Therapeutics (ZVRA) stake by 126% in Q1 2026, buying an estimated $130K and bringing the position to 25,941 shares worth $242K. The position accounts for 0.02% of the portfolio, ranked #814.

Prelude Capital Management first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Prelude Capital Management held 25,941 shares of Zevra Therapeutics worth $242K as of Q1 2026.
  • Prelude Capital Management bought 14,441 Zevra Therapeutics shares in Q1 2026, an estimated $130K.
  • Zevra Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #814 holding.
  • Prelude Capital Management first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.